EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
- Badari Andukuri
- 2 hours ago
- 2 min read
The European Commission has published its inaugural Joint Clinical Assessment (JCA), officially activating the EU’s modernized Health Technology Assessment (HTA) framework under Regulation (EU) 2021/2282.
What is the first drug assessed under Joint Clinical Assessment?
Drug: Ojemda
The first finalized review evaluates the targeted therapy Ojemda (tovorafenib).
Target Indication: Pediatric low-grade glioma.
Clinical Context: This represents the most commonly diagnosed brain tumor in children.
Report Scope: The dossier provides a comparative analysis of the drug's therapeutic value, safety data, and any evidence limitations relative to existing standards of care.
What are the expected advantages of Joint Clinical Assessment?
The revamped JCA model fundamentally alters how novel therapeutics are processed in Europe by moving away from fragmented reviews.
Unified Scientific Base: Member States now share a single, centralized clinical evaluation.
Reduced Redundancy: The framework eliminates the need for parallel, country-specific clinical assessments.
Accelerated Timelines: Harmonized data aims to speed up regulatory workflows and deliver innovative medicines to patients faster.
Next Steps for Market Access
The HTA Member State Coordination Group formally endorsed the findings on April 30. The complete assessment, alongside the manufacturer’s dossier and an executive summary, is now live on the European Commission's portal.
Individual national health authorities will now utilize this centralized clinical evidence to guide their localized pricing and reimbursement negotiations.
What is Stakeholders Perspective
Pierluigi Russo, Technical and Scientific Director at the Italian Medicines Agency, highlighted the milestone as a breakthrough in cross-border collaboration. He emphasized that utilizing a shared methodology equips national agencies with a robust, unified evidence base to make faster, highly informed decisions.
Since the framework went live in early 2025, the EU has initiated 18 joint assessments. The current pipeline is heavily weighted toward oncology treatments and advanced therapeutic medicinal products (ATMPs).